Business Context and Reporting Period
This Form 8-K was filed by Avalo Therapeutics, Inc. on July 20, 2023. The filing addresses a material default under an existing venture loan agreement and the subsequent entry into a forbearance agreement with institutional lenders. The company is a biopharmaceutical firm focused on developing therapies for rare diseases.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $4.5 million as of July 20, 2023 (preliminary and unaudited).
- Debt Status: The company is in a state of "Existing Default" under a Venture Loan and Security Agreement issued in June 2021 due to a material adverse change in the business.
- Liquidity Constraints: Under the new Forbearance Agreement, the company must maintain a minimum cash balance of $3.0 million plus 100% of future equity sale proceeds in controlled accounts.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the reporting period.
Material Changes and Events
- Default and Forbearance: Lenders asserted a default on July 20, 2023. The company immediately entered a Forbearance Agreement, delaying enforcement of remedies until August 15, 2023, or the occurrence of a new default.
- Asset Sale Discussions: The company signed a non-binding Letter of Intent (LOI) to potentially sell its "800 Series" assets (AVTX-801, AVTX-802, AVTX-803). Terms include a $150,000 upfront payment and up to $45 million in contingent milestone payments.
Outlook, Risks, and Management Commentary
- Transaction Uncertainty: Management notes that the LOI for the asset sale is non-binding, and there is no assurance that definitive agreements will be reached or that the transaction will close.
- Financial Risk: The company faces immediate liquidity pressure, requiring strict adherence to the $3.0 million cash reserve covenant to avoid further default actions.
- Reporting Status: The cash balance of $4.5 million is preliminary and subject to change upon the completion of financial statement closing procedures and audits.
Investor Verification Checklist
- Verify the final audited cash balance as of July 20, 2023, to confirm compliance with the $3.0 million minimum reserve requirement.
- Monitor the status of the non-binding LOI for the 800 Series asset sale to assess the likelihood of securing the proposed $150,000 upfront payment.
- Review the full text of the Forbearance Agreement (Exhibit 10.1) for specific covenants and potential triggers for immediate default.
- Confirm whether the company can raise additional equity capital without violating the 100% proceeds sweep provision in the forbearance terms.